Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C

R. D'Ambrosio, L. Pasulo, M. Puoti, M. Vinci, M. Schiavini, S. Lazzaroni, A. Soria, F. Gatti, B. Menzaghi, A. Aghemo, F. Capelli, M.G. Rumi, L. Morini, A. Giorgini, M.G. Pigozzi, A. Rossini, F. Maggiolo, A. Pan, M. Memoli, O. SpinelliP. Del Poggio, V. Saladino, A. Spinetti, A. De Bona, A. Capretti, C. Uberti-Foppa, P. Bonfanti, N. Terreni, F. Menozzi, A.E. Colombo, O. Giglio, R. Centenaro, M. Borghi, C. Baiguera, V. Picciotto, S. Landonio, A. Gori, C. Magnani, F. Noventa, S. Paolucci, P. Lampertico, S. Fagiuoli

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)379-387
Number of pages9
JournalJournal of Hepatology
Volume70
Issue number3
DOIs
Publication statusPublished - 2019

Keywords

  • DAA
  • Effectiveness
  • Glecaprevir
  • HCV
  • Pibrentasvir
  • RAS
  • Real-life
  • Safety
  • SVR
  • bilirubin
  • glecaprevir plus pibrentasvir
  • interferon
  • virus RNA
  • adult
  • aged
  • Article
  • chronic hepatitis C
  • chronic kidney failure
  • clinical effectiveness
  • cohort analysis
  • depression
  • drug safety
  • drug tolerability
  • drug withdrawal
  • estimated glomerular filtration rate
  • fatigue
  • female
  • headache
  • Hepatitis C virus genotype 1
  • Hepatitis C virus genotype 2
  • Hepatitis C virus genotype 3
  • human
  • Human immunodeficiency virus infection
  • hypertensive crisis
  • insomnia
  • intention to treat analysis
  • jaundice
  • liver stiffness
  • longitudinal study
  • major clinical study
  • male
  • mixed infection
  • multicenter study (topic)
  • nausea
  • nonhuman
  • patient compliance
  • platelet count
  • priority journal
  • pruritus
  • relapse
  • retrospective study
  • side effect
  • sustained virologic response
  • treatment duration
  • treatment response
  • vomiting

Cite this